• About us
• Contact

Advertisement

Organisation › Details

Schering AG (FSE: SCH, NYSE: SHR)

Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic Imaging as well as Specialized Therapeutics for disabling diseases. As a global player with innovative products, Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work

It is planned that Schering AG will be renamed Bayer Schering Pharma Aktiengesellschaft. A corresponding resolution was passed at the Extraordinary General Meeting of Schering AG on September 13, 2006. Until the name change has been registered in the commercial register, the company will continue to operate under the name Schering AG. According to the resolution of the General Meeting, the Executive Board will not file an application for registration before December 1, 2006. *

 

	End	2006-12-29
	Group	Bayer (Group)
	Today	Bayer Schering Pharma AG
	Successor	Bayer Schering Pharma AG
	Industry	pharmaceutical
	Region	Berlin
	Country	Germany
	Street	178 Müllerstr.
	City	13353 Berlin
	Tel	+49-30-468-1111
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-12-30

Advertisement

More documents for Bayer (Group)

• [1] H. Lundbeck A/S. (5/13/24). "Press Release: Maria Alfaiate Appointed New Executive Vice President Commercial and Corporate Strategy at Lundbeck"....
• [2] Evotec SE. (4/30/24). "Press Release: Bayer and Evotec Collaborate to Advance Precision Cardiology". Berlin & Hamburg....
• [3] ProBioGen AG. (4/30/24). "Press Release: Change in Management". Berlin....
• [4] Aignostics GmbH. (3/14/24). "Press Release: Bayer and Aignostics to Collaborate on Next Generation Precision Oncology"....
• [5] BenevolentAI Ltd.. (1/24/24). "Press Release: BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer". London....
• [6] Bayer AG. (10/10/23). "Press Release: Bayer Invests 250 million USD in New Cell Therapy Manufacturing Facility in the U.S. [Not intended for US and UK Media]". Berlin....
• [7] Twist Bioscience Corporation. (10/5/23). "Press Release: Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million". Hamburg & Singapore....
• [8] Bayer AG. (9/21/23). "Press Release: Bayer to Collaborate with Hologic in Breast cancer Imaging [Not intended for U.S. and UK Media]". Berlin....
• [9] Bayer AG. (8/30/23). "Press Release: Strong Commitment to Modern Crop Protection Made in Europe. Bayer to Invest EUR 220 Million in New R&D Facility at Its Monheim Site". Monheim....
• [10] Bayer AG. (8/29/23). "Press Release: Gene Editing – Pairwise and Bayer Start New Five-year Multi-million Dollar Collaboration to Further Advance Short-stature Corn". Durham, NC & Monheim....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.